Thomas Johnson, MD
Allergy/ Immunology · North Andover, MANPI 1922090430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 29.4% of the total. Among allergy/ immunology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$699
- GSK$422
- Pfizer$407
- AbbVie$367
- Biocryst US Sales Co., LLC$299
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,24899%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,555 |
| Sanofi | 31 | $699 |
| GSK | 22 | $422 |
| Pfizer | 26 | $407 |
| AbbVie | 20 | $367 |
| Biocryst US Sales Co., LLC | 10 | $299 |
| Pharming Healthcare, Inc. | 12 | $283 |
| Biohaven Pharmaceuticals, Inc. | 8 | $212 |
| Genentech USA, Inc. | 8 | $121 |
| Novartis | 4 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $83 |
| Grifols USA, LLC | 5 | $81 |
| Octapharma USA, Inc. | 3 | $63 |
| LEO Pharma Inc. | 3 | $59 |
| Kaleo, Inc. | 2 | $55 |
| Amgen | 2 | $45 |
| Cycle Pharmaceuticals Inc | 2 | $43 |
| Biocryst Pharmaceuticals, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Merck | 2 | $38 |
| GC Biopharma USA, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $32 |
| CSL Behring | 1 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Greer Laboratories, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,297 in reported general payments places this provider in the 95th percentile of 24 allergy/ immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 79 | $308,741 |
| XolairOmalizumab | 54 | $197,437 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $128,393 |
| CibinqoAbrocitinib | 12 | $113,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $77,412 |
| EliquisApixaban | 34 | $25,926 |
| JardianceEmpagliflozin | 14 | $22,909 |
| OzempicSemaglutide | 23 | $21,535 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $17,419 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,324 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,831 |
| Epinephrine | 29 | $4,284 |
| Celecoxib | 12 | $3,143 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,695 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerCibinqo, Eliquis | $407 | $139,00646 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $422 | $86,736120 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,555 | $24,25051 claims |
| Boehringer IngelheimJardiance | $38 | $22,90914 claims |
| AbbVieSynthroid | $367 | $70413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 allergy/ immunology providers in Massachusetts.
Other allergy/ immunology in North Andover
- Carolyn BalohBoston$211
- David SloaneChestnut Hill$93
- Sylvie Abi-YounesNorwood$74
- Lora BankovaChestnut Hill$23
- Patrick BrennanBoston$0
- Parul KothariChestnut Hill$0
- Anna FeldwegChestnut Hill$0
- Qura Tul Ain RashidBoston$0
- Amy LevinBoston$0
- George HuangBoston$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.